Sienna Biopharma: Eyes record low as acne drug misses trial goals

Sienna Biopharmaceuticals

30/07/2018 12:41

** Drug developer's shares  SNNA.O  fall ~23 pct premarket
to $12.11, set to open at their lowest ever at current levels 
    ** Says two pivotal trials testing co's experimental acne
drug SNA-001 did not meet their main goals  urn:newsml:reuters.com:*:nL4N1UQ48G
    ** Sienna went public a year ago and specializes in
developing dermatological drugs  urn:newsml:reuters.com:*:nGNXbgwLbQ 
    ** SNNA top pct loser across U.S. exchanges before the bell 
 
    ** As of Friday's close, SNNA shares have slipped 13.5 pct
this year   

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))